Introduction
============

Extraintestinal pathogenic *Escherichia coli* (ExPEC) isolates cause various infections with considerable morbidity and mortality. This fraction of *E. coli* isolates is the most common cause of urinary tract infections, both in the community and health-care centers.[@b1-idr-12-893]--[@b3-idr-12-893] The majority of these infections are caused by strains possessing the ability for colonization and survival in a specific niche and expressing an arsenal of virulence determinants.[@b4-idr-12-893],[@b5-idr-12-893] Treatment options are limited, due to the rise in prevalence of antibiotic-resistant strains.

Molecular epidemiology techniques, eg, multilocus sequence typing, are widely used to study ExPEC lineages, and sequence types (STs) 69, 73, 95, and 131 have been reported as pandemic clones among ExPEC isolates recovered from human infections.[@b6-idr-12-893]--[@b9-idr-12-893] In a UK study, consistent prevalence of these four STs among ExPEC isolates from urinary and bloodstream infections has been shown. Collectively, they comprised 45% of the ExPEC strains from community and hospital urine samples recovered in 2007--2009 and 2007--2008 in North West England and the East Midlands, respectively, as well as 58% of those from bacteremia in northern England in 2010--2012.[@b10-idr-12-893] In contrast, there is no published report about the prevalence or phenotypic and genetic traits of these major STs among *E. coli* clinical isolates from Iran.

Identification of and distinguishing the major STs by rapid diagnostic tests could thus be helpful to select appropriate therapy before conventional susceptibility-test data become available. Despite the multilocus sequence-typing technique, which is a time-consuming and expensive method, simpler molecular strategies like the multiplex PCR designed and validated by Doumith et al might make testing more accessible to diagnostic laboratories.[@b10-idr-12-893] In this study, we used multiplex PCR to study the prevalence of the five major STs -- ST69, ST73, ST95, ST127, and ST131 -- among a collection of clinical *E. coli* isolates recovered from patients admitted to Kosar University Hospital in Semnan, Iran during a 1-year surveillance study. We also determined virulence/resistance-gene profiles and antibiotic-susceptibility patterns of these major pandemic clones, focusing especially on ST131 subclones.

Methods
=======

Strains
-------

The study was conducted at Kosar University Hospital which serves patients in Semnan (Iran) and provides medical and surgical care in all medical specialties. A total of 335 *E. coli* isolates were obtained from different wards of the hospital from March 2015 to March 2016. Isolates were recovered from different extraintestinal clinical specimens, including, urine, blood, wound, and respiratory samples. Medical records were reviewed to obtain demographic and clinical data. Samples were cultured on MacConkey agar and after an overnight 37°C incubation period, and single colonies with morphological Gram-negative characteristics were subjected to standard laboratory procedures guidelines. *E. coli* isolates were identified as lactose-fermenting, citrate- and urease-negative and indole-positive. A total of 335 nonduplicate clinical isolates of *E. coli* from 335 patients admitted to the hospital were taken for this study. Isolates were taken as part of routine hospital procedure; therefore patient consent was not required. This study was approved by Semnan University of Medical Sciences with the ethics codes IR.SEMUMS.REC.1395.19 and IR.SEMUMS.REC.1395.18.

Phylogrouping and sequence-typing PCR
-------------------------------------

DNA templates were extracted for PCR by cetyltrimethylammonium bromide.[@b11-idr-12-893] Major *E. coli* phylogroups (A, B1, B2, C, D, E, and F) were determined by multiplex PCR.[@b12-idr-12-893] The major ExPEC STs (ST131, ST95, ST73, ST69, and ST127) were identified as described previously.[@b10-idr-12-893] Moreover, *E. coli* isolates belonging to phylogroups B2, D, and F were subjected to a second *gyrB*--*mdh* multiplex PCR to screen for the detection of single-nucleotide polymorphisms in *mdh* and *gyrB* associated with the ST131 clone. The *H30* and *H30*-Rx subclones of ST131 isolates were detected, and the two most common O types, O25b and O16, were screened by PCR among study ST131 isolates.[@b13-idr-12-893]

Antimicrobial-susceptibility testing
------------------------------------

Antibiotic-susceptibility profiles were obtained for all *E. coli* isolates using the standard disk-diffusion method on Mueller-- Hinton agar. Clinical Laboratory Standard Institute (CLSI) recommendations for antimicrobial-susceptibility testing were followed.[@b14-idr-12-893] Isolates with intermediate susceptibility patterns were categorized as resistant. Carbapenem-resistant isolates were those isolates with an inhibition zone of \<23 mm to any of imipenem, meropenem, or ertapenem.[@b14-idr-12-893] The resistance score was the number of antibiotics to which an isolate was resistant.[@b15-idr-12-893] Multidrug-resistant (MDR) isolates were those resistant to at least one representative of three or more antimicrobial classes.[@b15-idr-12-893] Extended-spectrum β-lactamase (ESBL)-producing isolates were detected by phenotypic combined-disk testing according to the recommendations of the CLSI.[@b14-idr-12-893]

Detection of resistance genes
-----------------------------

Isolates harboring resistance determinants, including carbapenemases (*bla*~NDM~, *bla*~OXA-48~, *bla*~IMP~-, *bla*~VIM~-, and *bla*~KPC~),[@b13-idr-12-893] ESBLs (*bla*~TEM~-, *bla*~SHV~-, and *bla*~CTX-M~ groups 1, 2, 8, 9, and 25), and plasmid-mediated quinolone resistance (*qnrA*, *qnrB*, *qnrS*, and *aac6Ib-cr*) were detected by multiplex PCR according to previously published methods.[@b13-idr-12-893] Moreover, isolates were screened for the presence of 16S rRNA methylase genes (*armA*, *rmtB*, and *rmtC*) and aminoglycoside-resistance determinants, including *aac6-Ib*/*aac3-IIa* genes.[@b16-idr-12-893] As positive controls, previously characterized isolates carrying resistance genes were used in this study.

Virulence-factor determination
------------------------------

The presence of 28 putative virulence genes was assessed by multiplex PCR.[@b15-idr-12-893] Isolates carrying two or more of the five markers, including *afaDrBC*, *papAH*, and/or *papC*, *sfa*, *kpsM II*, or *iutA* were presumed ExPEC, and isolates that tested positive for three or more of the four genes *chuA*, *fyuA*, *vat*, and *yfcV* were considered uropathogenic *E. coli* UPEC, as described previously.[@b17-idr-12-893] The number of unique virulence factors (VFs) detected for each isolate, counting the *PAI* marker as one, was considered the aggregate VF score.[@b17-idr-12-893]

Statistical analysis
--------------------

Fisher's exact test and the Mann--Whitney *U* test were used to compare proportions and scores, respectively. Principal-coordinate analysis, a multidimensional scaling method analogous to principal-component analysis, was used to collapse the molecular data set for simplified between-group comparisons.[@b18-idr-12-893] Groups were compared on each of the first three coordinates, which captured most of the variance within the data set, using a two-tailed *t*-test.

Results
=======

Detection of major STs
----------------------

With multiplex PCR, five major STs were detected among 151 (45%) of collected *E. coli* isolates. These isolates are detailed in [Table 1](#t1-idr-12-893){ref-type="table"}. Compared with the other four STs, ST131 isolates were significantly associated with older patients (mean and median 69.17 and 74.1 vs 60.4 and 64.5, *P*\<0.05). The five major STs were distributed similarly by specimen types and sex.

Relationships among phylogroups and major STs
---------------------------------------------

The phylogroups of the studied isolates are detailed in [Figure 1](#f1-idr-12-893){ref-type="fig"}. ST73 and ST95 were detected in phylogroups B1/B2 and A/B1/B2, while ST69 and ST127 were detected among all phylogroups, except A/C and D/E.

Relationship between antimicrobial resistance and STs
-----------------------------------------------------

Antimicrobial-resistance rates obtained for five major STs are represented in [Table 2](#t2-idr-12-893){ref-type="table"}. Overall, 14 (9.2%) of 151 isolates (including seven ST95, five ST127, and one for each of ST69 and ST73) remained susceptible to all antimicrobials tested. Except for imipenem and meropenem, ST131 isolates showed higher rates of resistance compared to the other four major STs, exhibiting high prevalence (\>85%) of resistance to aztreonam, fluoroquinolones, and cefotaxime, as well as MDR phenotype.

Among the non-ST131 isolates, ST69 was characterized by a prevalence of 50% resistance to amoxicillin--clavulanate as well as a high rate (41.7%) of MDR phenotypes and trimethoprim--sulfamethoxazole resistance (91.7%), which were the highest rates among the four major STs. The highest aggregate resistance score was detected in the ST131 clone (median 7), and decreased progressively through ST73, ST69, ST127, and ST95 (medians, 4, 2.50, 2, and 1, respectively).

Relationship between resistance genes and STs
---------------------------------------------

The frequency of resistance determinants among the five major STs is shown in [Table 3](#t3-idr-12-893){ref-type="table"}. Of the 88 ciprofloxacin-resistant isolates, 60 (68.2%) harbored *aac6Ib-cr* (*P*=0.004). While the prevalence of *aac6Ib*/*aac3IIa* genes among ST127 isolates was higher than other STs, the differences were borderline (*P*=0.06 for both genes) and not significant. Furthermore, resistance to gentamicin and tobramycin was significantly associated with the prevalence of *aac3IIa*, *aac6Ib, aac6Ib-cr*, and *armA* (*P*\<0.05 for all). While the carbapenemase genes *bla*~OXA-48~ and *bla*~NDM~ were found mostly among ST131 isolates (*P*\<0.05), higher ertapenem resistance in this clone compared to other STs did not reach statistical significance. The prevalence rates of *armA*, *qnrB*, *qnrS*, *bla*~TEM~, CTX-M-G2, and CTX-M-G9 were higher among 74 non-ST131 isolates, reaching statistical significance for the latter resistance-gene cluster (*P*=0.002).

Relationships among STs and virulence factors
---------------------------------------------

Based on the first two coordinates of a principal-coordinate analysis based on 28 studied virulence determinants, the virulence profiles of ST131 strains were highly distinctive, which significantly differentiated these isolates from other major ST isolates, whether these were considered collectively (*P*\<0.001, one coordinate only) or by individual subset (*P*\<0.001 for two or three coordinates per comparison). When the coordinate 1--coordinate 2 plane was plotted, variance of 45.5% was captured and the ST131 isolates clustered tightly in the lower half, which separated them from the other isolates ([Figure 2](#f2-idr-12-893){ref-type="fig"}).

With univariate analysis, aggregate virulence-profile differences were explored for individual virulence genes. Nine virulence genes were significantly more prevalent among ST131 isolates, while eleven virulence genes were detected significantly among the non-ST131 isolates ([Table 4](#t4-idr-12-893){ref-type="table"}). ST131 isolates showed lower aggregate virulence scores (median) than ST73, ST95 (significantly), and ST127 (insignificantly), and were only slightly higher than among ST69 isolates ([Table 4](#t4-idr-12-893){ref-type="table"}).

The 28 virulence determinants tested were detected at least once, with the lowest rate of 0.7% (*ibeA*) to the highest rate of 92% (*fyuA*). Nearly 56% of the isolates were positive for the group II capsule-synthesis gene, with k5 accounting for 79.8% of the *kpsM* II-positive isolates. Overall, the five major STs were considerably different in VF content, from ST69 with the lowest VF score (mean 7.79, median 8.50), to ST73 with the highest VF score (mean 14.92, median 16). Despite the higher carriage rates of different *pap* genes among four major STs, ST131 isolates showed lower prevalence of these adhesion genes (mainly *papC* and *papEF*). A negative association was detected between the carriage of *sfafocDE* and *iroN* genes with ST131 isolates, while the *sat* gene was mostly harbored by this clone. Among the different STs, *PAI*, *cnf1*, and *usp* had negative associations with the ST69 clone ([Table 4](#t4-idr-12-893){ref-type="table"}). Furthermore, the lowest rates of ExPEC and UPEC fractions among study isolates were found in this clone.

Eight of the 77 ST131 isolates belonged to the O16 subgroup and *H30*-negative and fluoroquinolone-susceptible, while the remaining 69 isolates were O25b- and *H30*-positive and fluoroquinolone-resistant, with a higher prevalence of ExPEC fraction compared to O16 (68 \[98.5%\] vs 5 \[62.5%\], *P*=0.003). The prevalence of four virulence genes -- *afaDrBC* (eight \[11.6%\] vs four \[50%\], *P*\<0.01), *sat* (68 \[98.6%\] vs six \[75%\], *P*=0.02), *k5* (37 \[53.6%\] vs one \[12.5%\], *P*\<0.05), and *PAI* (67 \[97%\] vs six \[75%\], *P*\<0.05) -- were significantly different between the O25b and O16 subgroups ([Figure 3](#f3-idr-12-893){ref-type="fig"}). Resistance rates of the O16 subgroup against imipenem, cefepime, amoxicillin--clavulanate, piperacillin--tazobactam, ampicillin--sulbactam, and trimethoprim--sulfamethoxazole were higher than O25b, but were not statistically significant ([Figure 4](#f4-idr-12-893){ref-type="fig"}). The *H30Rx* subclone was detected in 31 (45.6%) of the 68 *H30*-positive isolates.

Relationship between ciprofloxacin resistance and virulence/resistance scores
-----------------------------------------------------------------------------

Based on ciprofloxacin susceptibility, virulence and aggregate resistance scores were compared between ST131 and the other four major ST isolates. Among ciprofloxacin-susceptible isolates, VF scores were high between ST131 and non-ST131 isolates (median ST131 vs non-ST131 10 vs 12, *P*=0.32). In contrast, among ciprofloxacin-resistant isolates, the ST131 clone showed much higher VF scores (median 11) than non-ST131 isolates (median 9, *P*=0.019; [Figure 5A](#f5-idr-12-893){ref-type="fig"}). For aggregate resistance scores, a significant difference was detected between two groups of ciprofloxacin-susceptible isolates (median ST131 vs non-ST131 7.50 vs 2, *P*=0.013); however, the difference did not reach statistical significance for ciprofloxacin-resistant isolates (median ST131 vs non-ST131 7 vs 6, *P*=0.064; [Figure 5B](#f5-idr-12-893){ref-type="fig"}).

Discussion
==========

In the present study, we assessed 335 clinical *E. coli* isolates from extraintestinal specimens collected from patients admitted to Kosar University Hospital in Semnan, Iran during March 2015 to April 2016 for five major STs, phylogroup, and virulence/resistance genes, and compared these results with resistance phenotype, specimen type, and host age. To our knowledge, this is the first study to screen for major STs of *E. coli* within a set of systematically collected *E. coli* clinical isolates from Iran.

The antibiotic-resistant phenotypes seen here mirror more general patterns, with multiresistance, particularly to cephalosporins, fluoroquinolones, and gentamicin, mainly detected among the ST131 clone. In contrast, ST69 isolates were mostly resistant to trimethoprim--sulfamethoxazole and showed the highest rate of MDR phenotypes among 74 non-ST131 isolates. Similarly, the majority of ST73, ST95, and ST127 isolates were susceptible or resistant to no more than two classes of antibiotics.

One of the major ST clones reported among UPEC isolates is ST73.[@b19-idr-12-893] Our data emphasize the increased virulence of this clone to humans. In fact, the highest virulence scores in our data were detected among ST73 (median 16), together with ST95. With one exception, ST73 isolates showed higher rates of VFs (mean, median, and range) compared to ST69 strains. The *traT* gene was mostly detected among ST69 isolates. This finding has been reported in previous surveys.[@b20-idr-12-893] The traT protein is responsible for development of a resistance phenotype against serum bactericidal activity, and may confer additional advantage to ST69 isolates. Despite the lowest rates of ExPEC and UPEC among studied ST69 isolates compared to other STs, the success of this clone can also be due to the presence of a higher rate of an MDR phenotype, especially to trimethoprim--sulfamethoxazole, selected by the high prescription of this drug, freely available in Iranian pharmacies.

In comparison with ST69, the presence of *PAI*, *usp*, *iroN*, *kpsmTII*, *k5*, *cnf1*, *vat*, *hlyA*, *yfcV*, and *sfa* were significantly associated with ST73 (*P*\<0.05 for all). In a large study of *E. coli* from food, animals, and humans conducted by Manges et al, ST73 exclusively was detected among isolates from humans, showing food sources are unlikely. As such, it seems that ST73 isolates are human pathogens, and their unnoticed circulation in gut microbiota increases the chance of different extraintestinal infections in those with predisposing conditions.[@b21-idr-12-893]

The ST95 clone has been shown to be associated with avian pathogenic *E. coli* (APEC),[@b22-idr-12-893] and isolates of this clone are recovered mainly from food.[@b23-idr-12-893] Some of the reference strains, including UPEC strains UTI189 and NU14, and the neonatal meningitis strain RS218 are ST95,[@b23-idr-12-893] and in a recent study *svg*-gene carriage was used as a detection marker for identification of the ST95 clone among a group of APEC and ExPEC isolates.[@b24-idr-12-893] Our data showed the highest rate of ExPEC-positive isolates among this clone, and ST95 isolates were associated with the carriage of five genes (*iutA*, *ompT*, *iss*, *hlyF*, and *iroN*) which have been shown to correspond to APEC pathotypes.[@b25-idr-12-893] Similarly, ST95 showed the lowest resistance score and MDR phenotype, together with ST127, which emphasizes the inverse relationship between the prevalence of virulence genes and resistant phenotypes.

In our study, the broad range of VF genes screened revealed VF patterns were significantly associated with different STs. ST127, which has been reported to be the cause of pyelonephritis,[@b26-idr-12-893] showed lower rates of UPEC than ST73, ST95, and ST131 clones. However, ST127 isolates were associated with higher rates of some adhesions and toxins, especially *papACEFGII*, *sfa*, *vat* and *cnf1*, compared to other STs. Infections caused by isolates with such virulence potential may result in extensive exposure to antibiotics and increase the chances of acquisition of antibiotic-resistance determinants,[@b19-idr-12-893] as the highest rates of *aac6Ib, aac6Ib-cr*, and *aac3IIa* carriage, which mediate the low-level-resistance phenotype to aminoglycosides/fluoroquinolones were detected among this clonal lineage.

The basis for the O25b-ST131 serogroup's impressive epidemiological success, which contrasts with the limited success of the O16 subclone, needs to be studied further. We found that among ciprofloxacin-resistant isolates, despite the similar rates of MDR phenotype and ExPEC fraction between ST131 (all *H30* subclones) and non-ST131 isolates, the ST131 clone showed more extensive virulence profiles. In contrast, among ciprofloxacin-susceptible isolates, ST131 strains (all non-*H30* and O16) had a major advantage over other STs for extent of resistance and comparably extensive virulence profiles and ExPEC fraction. As such, among ciprofloxacin-resistant isolates, *H30* and *H30Rx* subclones have multiple factors favoring their superiority over other ST clones. Among ciprofloxacin-susceptible isolates, competition with other phylogroup B2 isolates may have limited O16-ST131 epidemiological success, and lower virulence determinants (although the difference was not significant in our study) are a determinant of this limitation.

Compared to the other four major STs, the study ST131 isolates showed distinctive virulence profiles that lacked some adhesions like fimbriae, but indicated significant reliance on nonfimbrial adhesions (*afaDrBC*). With some minor differences, study ST131 isolates were seen to harbor a collection of VFs similar to those reported from Spain,[@b27-idr-12-893] the UK,[@b28-idr-12-893] and US.[@b18-idr-12-893] It has been shown that the O25b subgroup has high virulence potential, which is corroborated here, but the number of O16 serogroups in our study isolates may have limited the ability to differentiate significantly between the O25b and O16 serogroups on the basis of virulence and multidrug resistance. Despite the lower number of O16-ST131 isolates, higher rates of resistance were detected against trimethoprim--sulfa-methoxazole, piperacillin--tazobactam, ampicillin--sulbactam, amoxicillin--clavulanate, and cefepime compared to the O25b serogroup. Therefore, it seems that ST131 clonal subsets exhibit distinctive associations with drug resistance, virulence contents, and host subsets, corroborating the importance of considering these subsets individually, rather than lumping them together as a single ST131 clone.[@b15-idr-12-893]

Conclusion
==========

We have described the virulence/antimicrobial resistance and phylogenetic diversity of ExPEC isolates, with particular reference to five major ST clones. ST127 has high adhesion potential, harbors plasmid-mediated *aac* genes, and warrants closer attention. The highest prevalence of antimicrobial resistance and virulence scores are linked to ST131, including its *H30*-predominant subgroup, and ST73. Coexpression of drug resistance and virulence among the ST131 clonal group along with widespread dissemination among locales underline its epidemiological superiority over other clones.
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![Prevalence of five major sequence types (STs) among seven phylogroups.](idr-12-893Fig1){#f1-idr-12-893}

![Principal coordinate--analysis plot for 151 *Escherichia coli* isolates belonging to five major sequence types (STs).\
**Notes:** Principal-coordinate analysis based on 28 virulence genes. Coordinate 1 and 2 captured 25.5% and 20% of variance in the data set, respectively (total 45%).](idr-12-893Fig2){#f2-idr-12-893}

![Virulence genotypes of 77 ST131 *Escherichia coli* isolates based on O25b and O16 subgroups.\
**Note:** \**P*≤0.05 between two subgroups.\
**Abbreviation:** ExPEC, extraintestinal pathogenic *E. coli*.](idr-12-893Fig3){#f3-idr-12-893}

![Antimicrobial-resistance rate (%) of 77 ST131 *Escherichia coli* isolates based on the O25b and O16 subgroups.\
**Note:** \*Significant difference (*P*\<0.05).\
**Abbreviations:** ESBL, extended spectrum β-lactamase; MDR, multidrug resistance; SXT, trimethoprim--sulfamethoxazole.](idr-12-893Fig4){#f4-idr-12-893}

![Virulence and resistance among ST131 and non-ST131 *Escherichia coli* isolates within two ciprofloxacin-resistance groups.\
**Notes:** Box-and-whisker plots show group medians (heavy horizontal bar) and maximum/minimum values (light horizontal bars). *P*-values determined by Mann--Whitney *U* test (two-tailed) shown for ST131 vs non-ST131 comparisons when *P*\<0.05. (**A**) Virulence scores (number of distinct virulence genes) among ST131 vs non-ST131 isolates within each resistance group; (**B**) resistance (R) scores among ST131 isolates vs non-ST131 isolates within each resistance group.\
**Abbreviations:** VF, virulence factor; ST, sequence type; NST, non-ST.](idr-12-893Fig5){#f5-idr-12-893}

###### 

Distribution of major sequence types (STs) among clinical isolates

  ---------------------------------------------------------------------------------------------------------
                   Sex         n (%)       Age (mean, median), years   Sample, n (%)              
  ---------------- ----------- ----------- --------------------------- --------------- ---------- ---------
  **ST69 (24)**\   Female      14 (58.3)   59.2, 64.5                  18 (75)         4 (16.7)   2 (8.3)
  **ST73 (13)**                                                                                   

  Male             10 (41.7)                                                                      

  Female           11 (84.6)   62.3, 65    11 (84.6)                   2 (15.4)        0          

  Male             2 (15.4)                                                                       

  **ST95 (15)**    Female      11 (73.3)   57.3, 63                    15 (100)        0          0

  Male             4 (26.7)                                                                       

  **ST127 (22)**   Female      11 (50)     62.5, 68.5                  19 (86.4)       2 (9.1)    1 (4.5)

  Male             11 (50)                                                                        

  **ST131 (77)**   Female      44 (57.1)   69.1, 74.5                  65 (84.4)       8 (10.4)   4 (5.2)

  Male             33 (42.8)                                                                      
  ---------------------------------------------------------------------------------------------------------

###### 

Overall prevalence of antimicrobial resistance among five major sequence types (STs)

                                                             ST69                                ST73               ST95               ST127               ST131
  ---------------------------------------------------------- ----------------------------------- ------------------ ------------------ ------------------- ------------
  **Antibiotics**                                            **Insusceptible isolates, n (%)**                                                             
  Imipenem                                                   0                                   2 (15.4)           2 (13.3)           0                   2 (2.6)
  Meropenem                                                  0                                   1 (7.7)            1 (6.7)            0                   1 (1.3)
  Ertapenem                                                  0                                   3 (23.1)           2 (13.3)           1 (4.5)             10 (13)
  Ceftazidime                                                8 (33.3)                            2 (15.4)           4 (26.7)           4 (18.2)            59 (76.6)
   *P*-value**[a](#tfn1-idr-12-893){ref-type="table-fn"}**                                       **[0.008]{.ul}**   **[0.05]{.ul}**    **[0.001]{.ul}**    **0.0001**
  Cefepime                                                   2 (8.3)                             3 (23.1)           0                  4 (18.2)            45 (58.4)
   *P*-value                                                 **[0.002]{.ul}**                                       **[0.001]{.ul}**                       **0.0001**
  Cefotaxime                                                 9 (37.5)                            6 (46.2)           7 (46.7)           10 (45.5)           71 (92.2)
   *P*-value                                                 **[0.001]{.ul}**                                                          **[0.02]{.ul}**     **0.0001**
  Aztreonam                                                  9 (37.5)                            4 (30.8)           5 (33.3)           6 (27.3)            68 (88.3)
   *P*-value                                                 **[0.01]{.ul}**                     **[0.03]{.ul}**    **[0.02]{.ul}**    **[0.001]{.ul}**    **0.0001**
  Amoxicillin--clavulanate                                   12 (50)                             5 (38.5)           4 (26.7)           11 (50)             46 (59.7)
   *P*-value                                                                                                        **[0.05]{.ul}**                        **0.05**
  Piperacillin--tazobactam                                   1 (4.2)                             2 (15.4)           3 (20)             2 (9.1)             13 (16.9)
  Ampicillin--sulbactam                                      2 (8.3)                             5 (38.5)           3 (20)             5 (22.7)            34 (44.2)
   *P*-value                                                 **[0.004]{.ul}**                                                                              **0.002**
  Trimethoprim--sulfamethoxazole                             22 (91.7)                           7 (53.8)           5 (33.3)           8 (36.4)            53 (68.8)
   *P*-value                                                 **0.001**                                              **[0.02]{.ul}**    **[0.008]{.ul}**    
  Ciprofloxacin                                              5 (20.8)                            4 (30.8)           5 (33.3)           5 (22.7)            69 (89.6)
   *P*-value                                                 **[0.0001]{.ul}**                   **[0.04]{.ul}**    **[0.05]{.ul}**    **[0.0001]{.ul}**   **0.0001**
  Levofloxacin                                               2 (8.3)                             2 (15.4)           3 (20)             4 (18.2)            68 (88.3)
   *P*-value                                                 **[0.0001]{.ul}**                   **[0.007]{.ul}**   **[0.01]{.ul}**    **[0.001]{.ul}**    **0.0001**
  Amikacin                                                   2 (8.3)                             1 (7.7)            2 (13.3)           0                   8 (10.4)
  Gentamicin                                                 1 (4.2)                             0                  2 (13.3)           2 (9.1)             34 (44.2)
   *P*-value                                                 **[0.009]{.ul}**                    **[0.02]{.ul}**                                           **0.0001**
  Tobramycin                                                 3 (12.5)                            1 (7.7)            0                  3 (13.6)            36 (46.8)
   *P*-value                                                                                                        **[0.006]{.ul}**                       **0.0001**
  MDR                                                        10 (41.7)                           4 (30.8)           5 (33.3)           5 (22.7)            66 (85.7)
   *P*-value                                                                                     **[0.03]{.ul}**    **[0.05]{.ul}**    **[0.0001]{.ul}**   **0.0001**
  Resistance score (mean, median)                            3.17, 2.50                          3.54, 4            3, 1               2.77, 2             7, 7
  ESBL phenotype                                             9 (37.5)                            6 (46.2)           7 (46.7)           10 (45.5)           71 (92.2)
   *P*-value                                                 **[0.001]{.ul}**                                                          **[0.02]{.ul}**     **0.0001**

**Notes:**

Comparison between each ST with all other STs combined. Bold values indicate significant associations. *P*-values in rows shown for differences that were statistically significant (*P*\<0.05). Underlining indicates a negative association.

**Abbreviations:** MDR, multidrug resistance; ESBL, extended spectrum β-lactamase.

###### 

Prevalence of resistance determinants among different sequence types (STs)

                                                         ST69                           ST73               ST95              ST127              ST131
  ------------------------------------------------------ ------------------------------ ------------------ ----------------- ------------------ ------------
  **Resistance genes**                                   **Positive isolates, n (%)**                                                           
  *bla*~OXA-48~                                          3 (12.5)                       1 (7.7)            1 (6.7)           [0]{.ul}           25 (32.5)
   *P*-value[a](#tfn3-idr-12-893){ref-type="table-fn"}                                                                       **[0.008]{.ul}**   **0.001**
  *bla*~NDM~                                             0                              0                  0                 0                  14 (18.2)
   *P*-value                                                                                                                                    **0.001**
  *bla*~TEM~                                             20 (83.3)                      6 (46.2)           8 (53.3)          16 (72.7)          51 (66.2)
  *bla*~SHV~                                             8 (33.3)                       5 (38.5)           7 (46.7)          7 (33.3)           35 (46.1)
  *qnrB*                                                 7 (29.2)                       3 (23.1)           3 (20)            2 (9.1)            15 (19.5)
  *qnrS*                                                 11 (45.8)                      1 (7.7)            1 (6.7)           3 (13.6)           9 (11.7)
   *P*-value                                             **0.0001**                                                                             
  *aac6Ib-cr*                                            9 (37.5)                       5 (38.5)           8 (53.3)          16 (72.7)          50 (64.9)
   *P*-value                                             **[0.04]{.ul}**                                                                        
  *aac6Ib*                                               8 (33.3)                       5 (38.5)           3 (20)            16 (72.7)          48 (62.3)
   *P*-value                                             **[0.045]{.ul}**                                  **[0.01]{.ul}**                      **0.02**
  *aac3IIa*                                              9 (37.5)                       3 (23.1)           6 (40)            16 (72.7)          47 (61)
   *P*-value                                                                            **[0.03]{.ul}**                                         
  *armA*                                                 5 (20.8)                       1 (7.7)            1 (6.7)           2 (9.1)            5 (6.5)
   *P*-value                                             **0.05**                                                                               
  CTX-M-G1                                               19 (79.2)                      6 (46.2)           12 (80)           17 (77.3)          64 (83.1)
   *P*-value                                                                            **[0.008]{.ul}**                                        
  CTX-M-G2                                               1 (4.2)                        0                  0                 1 (4.5)            1 (1.3)
  CTX-M-G8                                               0                              0                  0                 3 (13.6)           6 (7.8)
  CTX-M-G9                                               14 (58.3)                      6 (46.3)           9 (60)            11 (50)            22 (28.6)
   *P*-value                                                                                                                                    **0.002**
  CTX-M-G25                                              0                              0                  1 (6.7)           0                  24 (31.2)
   *P*-value                                             **[0.01]{.ul}**                                                     **[0.02]{.ul}**    **0.0001**

**Notes:**

*P*-values shown for differences that were statistically significant (*P*\<0.05). Bold values indicate significant associations (*P*≤0.05); underlining indicates negative associations.

###### 

Prevalence of 28 virulence genes among different sequence types (STs)

                                   ST69                   ST73                  ST95                 ST127                  ST131                  ST131 vs other STs (%)   *P-*value[a](#tfn4-idr-12-893){ref-type="table-fn"}
  -------------------------------- ---------------------- --------------------- -------------------- ---------------------- ---------------------- ------------------------ -----------------------------------------------------
  **Positive isolates, n (%)**                                                                                                                                              
  Adhesions                                                                                                                                                                 
   *afaDraBC*                      0                      0                     1 (6.7)              3 (13.6)               12 (15.6)              5.4 vs 15.6              
   *papA*                          10 (41.7)              4 (30.8)              **11 (73.3)**        11 (50)                29 (37.7)              37.7 vs 48.6             
   *papC*                          16 (66.7)              7 (53.8)              **13 (86.7)**        16 (72.7)              **[33 (42.9)]{.ul}**   42.9 vs 70.3             **[0.001]{.ul}**
   *papEF*                         12 (50)                5 (58.5)              **11 (73.3)**        **15 (68.2)**          **[29 (37.7)]{.ul}**   37.7 vs 58.1             **[0.01]{.ul}**
   *F10papA*                       **[5 (20.8)]{.ul}**    7 (53.8)              **[1 (6.7)]{.ul}**   **[3 (14.3)]{.ul}**    **74 (96.1)**          96.1 vs 21.9             **0.0001**
   *papG II*                       10 (41.7)              4 (30.8)              **10 (66.7)**        **[2 (9.1)]{.ul}**     31 (40.3)              40.3 vs 35.1             
   *papG III*                      0                      1 (7.7)               1 (6.7)              **11 (50)**            **[0]{.ul}**           0 vs 17.6                **[0.0001]{.ul}**
   *sfafocDE*                      1 (4.2)                **12 (92.3)**         3 (20)               **10 (45.5)**          **[0]{.ul}**           0 vs 35.1                **[0.0001]{.ul}**
   *yfcV*                          **[1 (4.2)]{.ul}**     12 (92.3)             13 (86.7)            **[13 (59.1)]{.ul}**   **76 (98.7)**          98.7 vs 52.7             **0.0001**
  Toxins                                                                                                                                                                    
   *hlyF*                          4 (16.7)               2 (15.4)              **7 (46.7)**         1 (4.8)                **[1 (1.3)]{.ul}**     1.3 vs 19.2              **[0.0001]{.ul}**
   *hlyA*                          7 (29.2)               **10 (76.9)**         4 (26.7)             11 (50)                **[21 (27.3)]{.ul}**   27.3 vs 43.2             **[0.04]{.ul}**
   *vat*                           **[0]{.ul}**           **12 (92.3)**         **12 (80)**          **11 (50)**            **[0]{.ul}**           0 vs 47.3                **[0.0001]{.ul}**
   *cnf1*                          **[0]{.ul}**           **11 (84.6)**         1 (6.7)              **11 (50)**            20 (26)                26 vs 31.1               
   *sat*                           **[6 (25)]{.ul}**      6 (46.2)              **[3 (20)]{.ul}**    **[5 (22.7)]{.ul}**    **72 (93.5)**          93.5 vs 27               **0.0001**
   *cdtB*                          1 (4.2)                0                     0                    1 (4.5)                0                      0 vs 2.7                 
  Capsules                                                                                                                                                                  
   *kpsMT* II                      10 (41.7)              **12 (92.3)**         11 (73.2)            13 (59.1)              38 (49.4)              49.4 vs 62.2             
   *kpsMT* K5                      10 (41.7)              **11 (84.6)**         **[1 (6.7)]{.ul}**   11 (50)                38 (49.4)              49.4 vs 44.6             
   *neuC*                          0                      1 (7.7)               **8 (53.3)**         1 (4.5)                **[0]{.ul}**           0 vs 13.5                **[0.0001]{.ul}**
  Siderophores                                                                                                                                                              
   *iutA*                          **[10 (41.7)]{.ul}**   7 (53.8)              12 (80)              13 (59.1)              **71 (92.2)**          92.2 vs 56.8             **0.0001**
   *iroN*                          9 (37.5)               **13 (100)**          **9 (60)**           10 (45.5)              **[2 (2.6)]{.ul}**     2.6 vs 55.4              **[0.0001]{.ul}**
   *chuA*                          23 (95.8)              12 (92.3)             12 (80)              **[13 (59.1)]{.ul}**   **76 (98.7)**          98.7 vs 81.1             **0.0001**
   *fyuA*                          21 (87.5)              11 (84.6)             13 (86.7)            18 (81.8)              **76 (98.7)**          98.7 vs 85.1             **0.0001**
  Miscellaneous                                                                                                                                                             
   *ibeA*                          0                      0                     1 (6.7)              0                      0                      0 vs 1.4                 
   *usp*                           **[0]{.ul}**           12 (92.3)             11 (73.3)            **[11 (50)]{.ul}**     **76 (98.7)**          98.7 vs 45.9             **0.0001**
   *PAI*                           **[0]{.ul}**           12 (92.3)             13 (86.7)            13 (59.1)              **73 (94.8)**          94.8 vs 51.4             **0.0001**
   *traT*                          23 (95.8)              **[5 (38.5)]{.ul}**   12 (80)              18 (81.8)              **72 (93.5)**          93.5 vs 78.4             **0.0009**
  Protections                                                                                                                                                               
   *ompT*                          4 (16.7)               2 (15.4)              **7 (46.7)**         1 (4.8)                **[1 (1.3)]{.ul}**     1.3 vs 19.2              **[0.0001]{.ul}**
   *iss*                           4 (16.7)               2 (15.4)              **8 (53.3)**         2 (9.5)                **[1 (1.3)]{.ul}**     1.3 vs 21.9              **[0.0001]{.ul}**
  ExPEC                            **[13 (54.2)]{.ul}**   12 (92.3)             15 (100)             20 (90.9)              70 (90.9)              90.9 vs 81.1             
  UPEC                             **[1 (4.2)]{.ul}**     12 (92.3)             13 (86.7)            14 (63.6)              **76 (98.7)**          98.7 vs 54.1             **0.0001**
  VF score (mean, median, range)   7.79, 8.50, 3--13      14.92, 16, 6--19      14, 16, 3--18        11.32, 12.50, 2--20    11.96, 11, 4--17       11 vs 11.50              

**Notes:**

Significant differences between ST131 and all other STs combined. Bold values indicate significant associations (*P*≤0.05); underlining indicates negative associations.

**Abbreviations:** ExPEC, extraintestinal pathogenic *Escherichia coli*; UPEC, uropathogenic *E. coli*; VF, virulence factor.
